Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (273)	5/1/2002 12:41:56 PM
From: Dave	Read Replies (1) \| Respond to of 370

Vion's 1Q02 earnings, reported yesterday, is surprising. The company GROSSED $47,000 in income. Geez, you could make that by selling web banner space on a personal web page. $47K! At their current burn rate of $4M per quarter, they will start defaulting on their payroll and utility bills in 2Q03. Some months before that happens, key employees will have already packed up their bunsen burners and test tubes and walked. IS THERE NOT EVEN A PLAN FOR FIXING THIS COMPANY BEFORE THE MONEY RUNS OUT??? Dave

To: Jim Oravetz who wrote (273)	5/30/2002 12:52:49 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Genetically modified tumor-targeted bacteria with reduced virulence United States Patent 6,080,849 Bermudes , et al. June 27, 2000 Abstract The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors. -------------------------------------------------------------------------------- Inventors: Bermudes; David (Wallingford, CT); Low; Kenneth Brooks (Guilford, CT) Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT); Yale University (New Haven, CT) Appl. No.: 926636 Filed: September 10, 1997 snip.... -------------------------------------------------------------------------------- Processes for high-yield diastereoselective synthesis of dideoxynucleosides United States Patent 6,005,097 Chen , et al. December 21, 1999 Abstract The present invention relates to methods for substantially enhancing the stereoselective synthesis of .beta.-anomeric nucleoside analogs. In methods according to the present invention, the introduction of a phenylseleno group onto a blocked lactone sugar precursor may be selected so that the desirable phenylseleno substituent is introduced on the side of the blocked lactone away from the blocking group. This stereospecific introduction of the phenylseleno group in sugar precursor allows the synthesis of nucleoside analogs and in particular, 2',3',-dideoxy- and 2',3'-dideoxy-2',3'-didehydronucleoside analogs in very high yield. In certain preferred embodiments, the preferred phenylseleno blocked lactone is obtained in an amount representing approximately 90% or more of the total amount of the stereoisomers obtained. In even more preferred embodiments, the amount of the preferred stereoisomer is at least 95%, even more preferably at least about 97% of the total amount of phenylseleno blocked lactone produced. -------------------------------------------------------------------------------- Inventors: Chen; Shu-Hui (Hamden, CT); Li; Xiuyan (New Haven, CT) Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT) Appl. No.: 663674 Filed: June 14, 1996 snip.... -------------------------------------------------------------------------------- Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP United States Patent 5,869,676 Niu , et al. February 9, 1999 Abstract The present invention relates to improved, efficient chemical syntheses of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP). -------------------------------------------------------------------------------- Inventors: Niu; ChuanSheng (Cheshire, CT); Li; Jun (Hamden, CT); Li; Xiuyan (New Haven, CT); Doyle; Terrence W. (Killingworth, CT); Chen; Shu-Hui (Hamden, CT) Assignee: Vion Pharmaceuticals, Inc. (New Haven, CT) Appl. No.: 856559 Filed: May 15, 1997